JP2013505008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505008A5 JP2013505008A5 JP2012529295A JP2012529295A JP2013505008A5 JP 2013505008 A5 JP2013505008 A5 JP 2013505008A5 JP 2012529295 A JP2012529295 A JP 2012529295A JP 2012529295 A JP2012529295 A JP 2012529295A JP 2013505008 A5 JP2013505008 A5 JP 2013505008A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- patient
- responder
- standard
- training set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 4
- 102100031539 E3 ubiquitin-protein ligase RNF144B Human genes 0.000 claims 3
- 101001130266 Homo sapiens E3 ubiquitin-protein ligase RNF144B Proteins 0.000 claims 3
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 3
- 102000006381 STAT1 Transcription Factor Human genes 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 101000648265 Homo sapiens Thymocyte selection-associated high mobility group box protein TOX Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100028788 Thymocyte selection-associated high mobility group box protein TOX Human genes 0.000 claims 2
- 238000012512 characterization method Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
Claims (9)
- レスポンダーとして特徴付けられる患者を治療するための医薬の調製における、腫瘍関連抗原を含む組成物の使用、ここで該患者は以下の工程、
（ａ）患者由来のサンプルを、PSMB9, RNF144B, STAT1, TNFRSF9, 及びTOXからなる群より選択される１つ以上の遺伝子の遺伝子産物の発現差異について分析すること；および
（ｂ）工程（ａ）の結果に基づき、前記サンプルが由来する患者を、レスポンダーまたはノンレスポンダーとして特徴付けること
によりレスポンダーと決定される、前記使用。 - 前記特徴付け工程が、標準もしくはトレーニングセットを参照することによりまたは標準もしくはトレーニングセットとの比較により実施される、請求項１に記載の使用。
- 前記標準が、公知の臨床成績を有するサンプルである、請求項１または２に記載の使用。
- 前記比較が標準またはトレーニングセットから得られたパラメータを有するアルゴリズムを使用することにより実施される、請求項１〜３のいずれか１項に記載の使用。
- 患者をレスポンダーとして決定する工程及び該患者を療法のために選択する工程をさらに含む、請求項１〜４のいずれか１項に記載の使用。
- 癌治療に対するレスポンダー又はノンレスポンダーの特徴付けのための、PSMB9, RNF144B, STAT1, TNFRSF9及びTOXからなる群より選択される１以上の遺伝子の発現差異の同定のためのプローブの使用。
- 請求項１に記載の組成物がさらにアジュバントを含む、請求項１に記載の使用。
- 前記療法がMAGE A3免疫療法である、請求項１〜７のいずれか１項に記載の使用。
- 該アルゴリズムがPSMB9, RNF144B, STAT1, TNFRSF9からなる群から選択される１以上の遺伝子と表１に記載の１以上の遺伝子とを組み合わせて用い、かつ該遺伝子がトレーニングセットにおける変化に対し抵抗性である、請求項４に記載の使用。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27704609P | 2009-09-18 | 2009-09-18 | |
| US61/277,046 | 2009-09-18 | ||
| US27838709P | 2009-10-06 | 2009-10-06 | |
| US61/278,387 | 2009-10-06 | ||
| GBGB0917457.4A GB0917457D0 (en) | 2009-10-06 | 2009-10-06 | Method |
| GB0917457.4 | 2009-10-06 | ||
| PCT/EP2010/063751 WO2011033095A1 (en) | 2009-09-18 | 2010-09-17 | Method for identifying whether a patient will be responder or not to immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505008A JP2013505008A (ja) | 2013-02-14 |
| JP2013505008A5 true JP2013505008A5 (ja) | 2013-11-07 |
Family
ID=41393894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529295A Ceased JP2013505008A (ja) | 2009-09-18 | 2010-09-17 | 患者が免疫療法に対するレスポンダーかそうでなきかを同定するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110070268A1 (ja) |
| EP (1) | EP2478116A1 (ja) |
| JP (1) | JP2013505008A (ja) |
| KR (1) | KR20130055553A (ja) |
| CN (1) | CN102597269A (ja) |
| AU (1) | AU2010297248A1 (ja) |
| BR (1) | BR112012006088A2 (ja) |
| CA (1) | CA2773666A1 (ja) |
| EA (1) | EA201290107A1 (ja) |
| GB (1) | GB0917457D0 (ja) |
| IL (1) | IL218313A0 (ja) |
| MX (1) | MX2012003329A (ja) |
| SG (1) | SG179129A1 (ja) |
| WO (1) | WO2011033095A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2906523A1 (en) | 2013-03-15 | 2014-09-25 | Myriad Genetics, Inc. | Genes and gene signatures for diagnosis and treatment of melanoma |
| WO2016003810A1 (en) | 2014-07-02 | 2016-01-07 | Myriad Genetics, Inc. | Genes and gene signatures for diagnosis and treatment of melanoma |
| WO2016109546A2 (en) * | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
| JP2019514396A (ja) * | 2016-05-05 | 2019-06-06 | ナントミクス，エルエルシー | チェックポイント不全およびそれに関する方法 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| JP2023529026A (ja) * | 2020-06-01 | 2023-07-06 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用 |
| CN115495026B (zh) * | 2022-11-21 | 2023-03-10 | 杭州字节方舟科技有限公司 | 一种优化内存处理方法、装置、设备及存储介质 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| PT1584685E (pt) | 1998-02-05 | 2011-06-17 | Glaxosmithkline Biolog Sa | Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação |
| WO2000009159A1 (en) | 1998-08-10 | 2000-02-24 | Aquila Biopharmaceuticals, Inc. | Compositions of cpg and saponin adjuvants and methods thereof |
| TR200102191T2 (tr) | 1999-01-29 | 2001-12-21 | Corixa Corporation | HER-2/neu füzyon proteinleri. |
| EP1165778B1 (en) | 1999-03-11 | 2006-10-18 | GlaxoSmithKline Biologicals S.A. | Uses of casb618 polynucleotides and polypeptides |
| TR200103018T2 (tr) | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| PT1265915E (pt) | 2000-02-23 | 2011-02-07 | Glaxosmithkline Biolog Sa | Novos compostos |
| US20020076469A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| DE10127572A1 (de) * | 2001-05-30 | 2002-12-05 | Pathoarray Gmbh | Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen |
| US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20030124127A1 (en) * | 2001-12-06 | 2003-07-03 | Lijun Yang | Targeting leukemia cells |
| WO2003065806A1 (en) | 2002-02-04 | 2003-08-14 | Corixa Corporation | New immunoeffector compounds |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| NZ537125A (en) | 2002-06-11 | 2006-08-31 | Glaxosmithkline Biolog S | Immunogenic compositions |
| US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| WO2004076565A2 (en) * | 2003-02-25 | 2004-09-10 | Technical Knockout, Inc. | Improved coated weight plates, dumbbells and method of manufacture |
| CA2516182A1 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
| JP2007516692A (ja) * | 2003-03-07 | 2007-06-28 | アビアラデックス，インコーポレイティド | 乳癌の徴候 |
| US20060265138A1 (en) * | 2003-03-14 | 2006-11-23 | David Bowtell | Expression profiling of tumours |
| US20040241725A1 (en) * | 2003-03-25 | 2004-12-02 | Wenming Xiao | Lung cancer detection |
| US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| EP1631689A2 (en) * | 2003-05-28 | 2006-03-08 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| MXPA05012939A (es) | 2003-05-30 | 2006-05-17 | Astrazeneca Uk Ltd | Procedimiento. |
| EP1651775A2 (en) * | 2003-06-18 | 2006-05-03 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
| DE602004015626D1 (de) * | 2003-08-28 | 2008-09-18 | Ipsogen | Bei brustkrebs |
| US20060240441A1 (en) * | 2003-10-03 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
| WO2005044999A2 (en) * | 2003-11-05 | 2005-05-19 | New England Medical Center Hospitals, Inc. | Treatment with immunoregulatory t cells |
| US8187805B2 (en) * | 2004-02-09 | 2012-05-29 | Fuso Pharmaceutical Industries, Ltd. | Method of detecting nucleic acid and utilization thereof |
| US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
| WO2005108610A2 (en) * | 2004-04-05 | 2005-11-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for the selection of subjects for multiple sclerosis therapy |
| US7332281B2 (en) * | 2004-04-27 | 2008-02-19 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| WO2006054129A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| JP2008521412A (ja) * | 2004-11-30 | 2008-06-26 | ベリデックス・エルエルシー | 肺癌予後判定手段 |
| US20070059720A9 (en) * | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
| WO2006091776A2 (en) | 2005-02-25 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| GB0504302D0 (en) | 2005-03-02 | 2005-04-06 | Univ Dublin | Markers for melanoma |
| US20080193938A1 (en) | 2005-04-01 | 2008-08-14 | Yu Kun | Materials And Methods Relating To Breast Cancer Classification |
| WO2006124836A1 (en) | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| WO2007008583A2 (en) * | 2005-07-07 | 2007-01-18 | Kohne David E | Improved protein expression comparison assay results and applications |
| WO2007124578A1 (en) * | 2006-04-27 | 2007-11-08 | Universite De Montreal | Assessment and reduction of risk of graft-versus-host disease |
| EP2032719A2 (en) * | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| CN101821629A (zh) * | 2007-09-10 | 2010-09-01 | 诺瓦提斯研究基金会弗里德里克·米谢尔生物医学研究所 | 用于预测患有肝脏病毒性感染的受试者针对抗病毒疗法的应答的方法 |
| WO2009068621A1 (en) * | 2007-11-30 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Method for classifying cancer patients as responder or non-responder to immunotherapy |
-
2009
- 2009-10-06 GB GBGB0917457.4A patent/GB0917457D0/en not_active Ceased
-
2010
- 2010-09-17 KR KR1020127009956A patent/KR20130055553A/ko not_active Application Discontinuation
- 2010-09-17 US US12/884,407 patent/US20110070268A1/en not_active Abandoned
- 2010-09-17 MX MX2012003329A patent/MX2012003329A/es not_active Application Discontinuation
- 2010-09-17 EP EP10757757A patent/EP2478116A1/en not_active Ceased
- 2010-09-17 BR BR112012006088-0A patent/BR112012006088A2/pt not_active IP Right Cessation
- 2010-09-17 AU AU2010297248A patent/AU2010297248A1/en not_active Abandoned
- 2010-09-17 SG SG2012017869A patent/SG179129A1/en unknown
- 2010-09-17 EA EA201290107A patent/EA201290107A1/ru unknown
- 2010-09-17 CA CA2773666A patent/CA2773666A1/en not_active Abandoned
- 2010-09-17 CN CN2010800494497A patent/CN102597269A/zh active Pending
- 2010-09-17 WO PCT/EP2010/063751 patent/WO2011033095A1/en active Application Filing
- 2010-09-17 JP JP2012529295A patent/JP2013505008A/ja not_active Ceased
-
2012
- 2012-02-26 IL IL218313A patent/IL218313A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505008A5 (ja) | ||
| JP2020514413A (ja) | ペプチドワクチン | |
| MX2019003934A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| Brägelmann et al. | Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA | |
| JP2017055769A5 (ja) | ||
| KR20210086610A (ko) | 백신 조성물의 제조 방법 | |
| Solinas et al. | Tumor infiltrating lymphocytes in gastrointestinal tumors: controversies and future clinical implications | |
| JP2016537010A5 (ja) | ||
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| RU2010123381A (ru) | Способ и композиции для диагностического применения у раковых пациентов | |
| JP2010538609A5 (ja) | ||
| JP2020178667A (ja) | がん治療の効果および予後の予測方法および治療手段の選択方法 | |
| Xu et al. | The effect of acupuncture on tumor growth and gut microbiota in mice inoculated with osteosarcoma cells | |
| WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof | |
| JP2017503481A5 (ja) | ||
| Wentzensen et al. | Filling a gap in cervical cancer screening programmes | |
| Viet et al. | The REASON score: An epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma | |
| JP2018518980A5 (ja) | ||
| US11666644B2 (en) | Peptide vaccines | |
| JP2011527575A5 (ja) | ||
| EA201290107A1 (ru) | Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии | |
| JP2012504948A5 (ja) | ||
| Sheerin et al. | Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen | |
| Vasileva et al. | Adapted program for independent home rehabilitation for patients with ischemic stroke in the chronic period | |
| JP2016540726A5 (ja) |